PTC Therapeutics Provides Key Regulatory Updates

PTC Therapeutics announced that, based on recent feedback from the FDA, by mid-year they plan to re-submit an NDA for Translarna (ataluren) for Duchenne caused by nonsense mutations (also called premature stop codons).  We will keep the community updated on the progress. 

Read the full press release HERE